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Yoshihiro Seo, MD, PhD; Tomoko Ishizu, MD, PhD; Tomoko Machino-Ohtsuka, MD, PhD; Masayoshi Yamamoto, MD, PhD;
Takeshi Machino, MD, PhD; Kenji Kuroki, MD, PhD; Hiro Yamasaki, MD, PhD; Yukio Sekiguchi, MD, PhD; Akihiko Nogami, MD, PhD;
Kazutaka Aonuma, MD, PhD
Background-—Speckle tracking echocardiography (STE) is reported as a useful method to predict cardiac resynchronization
therapy (CRT) responders. This study aimed to identify the incremental value of a STE parameter to predict CRT responders.
Methods and Results-—We enrolled 171 patients from the Speckle Tracking imaging for the Assessment of cardiac
Resynchronization Therapy (START) study. CRT responders were deﬁned as patients with ≥15% reduction of left ventricular (LV)
end-systolic volume at 6 months post-CRT. Based on multivariable logistic regression analysis, incremental values of STE were
assessed by c-statistics, net reclassiﬁcation improvement (NRI)/integrated discrimination improvement (IDI), and decision curve
analysis. Six parameters (left bundle branch block or right ventricular pacing, use of beta-blocker, blood urea nitrogen ≤3.0 mg/dL,
LV end-systolic diameter ≤50 mm, mitral regurgitation index ≤40%, and STE parameter standard deviation of time from QRS onset
to ﬁrst peak on the circumferential strain curves [TSD] ≥116 ms) were identiﬁed as the determinants. Compared to the
multivariable logistic regression model without TSD (model 1), that with TSD (model 2) showed signiﬁcant improvement to predict
CRT responders: c-statistic (0.86 vs 0.77; P<0.001), NRI=0.19, P<0.001, and IDI=0.17, P<0.001. The decision curve of model 2
was higher than that of model 1 at threshold probabilities ≥0.2. Based on model 2, a START score was constructed. Compared to
the Multicenter Automatic Deﬁbrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) score, the decision
curve of the START score was higher than that of the MADIT-CRT score at threshold probabilities ≥0.2.
Conclusions-—Based on various statistical methods, this study revealed that STE had an incremental value to predict CRT
responders. ( J Am Heart Assoc. 2016;5:e003882 doi: 10.1161/JAHA.116.003882)
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C ardiac resynchronization therapy (CRT) is an establishednonpharmacological therapy for patients with advanced
heart failure characterized by left ventricular (LV) dysfunction
with LV ejection fraction (LVEF) ≤35% and LV dyssynchrony
with QRS duration ≥120 ms.1–3 The responses for CRT have
been widely assessed by LV reverse remodeling, which is
usually deﬁned as a ≥15% reduction of LV end-systolic volume
post-CRT. Based on the current guideline, the rate of CRT
responders is from 60% to 70%.1–3 The usefulness of
echocardiographic parameters to improve the response rate
to CRT has been controversial.4,5 Recently, speckle tracking
echocardiography (STE) has been reported as a useful imaging
method to detect CRT responders.6–8 In our Speckle Tracking
imaging for the Assessment of cardiac Resynchronization
Therapy (START) study, a STE parameter was revealed to be
an independent predictor of a CRT responder and was
associated with the clinical endpoints by multivariable stud-
ies.8 However, whether a STE parameter has incremental
value to the preceding factors associated with CRT responses
has not been well studied.9 Therefore, we hypothesized that a
multivariable diagnostic model consisting of signiﬁcant
parameters associated with CRT responses might be helpful
to quantify the incremental value of a STE parameter for the
prediction of CRT responders. Although the difference in the
area under the curve (AUC) of receiver operating character-
istic (ROC) analysis or concordance (c) statistics have been
widely used to express the incremental value of a new test/
biomarker, they have been criticized because of several
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limitations.9 To overcome the problems of ROC analysis, the
reclassiﬁcation table has been popular using some measures,
including net reclassiﬁcation improvement (NRI) and inte-
grated discrimination improvement (IDI).10 In addition, deci-
sion curve analysis (DCA) has been proposed to quantify the
added value of a parameter as a better method than NRI and
IDI.9,11–14 Thus, the aim of this study was to identify the
incremental value of a STE parameter to predict CRT
responders by these statistical methods.
Methods
Study Population
The START study was a prospective multicenter study to
assess the feasibility of STE to predict CRT responders. The
study design and results were published in December 2014.8
Patients were enrolled based on criteria that included
presence of congestive heart failure refractory to optimal
medical therapy and QRS duration ≥120 ms; New York Heart
Association (NYHA) class II, III, or IV; and LVEF ≤35%. Finally,
180 patients were enrolled from 17 Japanese centers
between September 2009 and August 2011, and clinical
follow-up was completed in September 2012. The study was
approved by the institutional review committee of the
University of Tsukuba Hospital (Tsukuba, Japan), and all
subjects gave informed consent.
CRT Volume Responders and Clinical Outcome
A volume responder to CRT was deﬁned as a patient with
reverse remodeling as indicated by a ≥15% reduction of LV end-
systolic volume at 6 months post-CRT. LV volume measure-
ments at 6 months were completed in 171 (95%) of the 180
patients. Six-month data in the remaining 9 patients could not
be assessed because of death from heart failure in 4, sudden
cardiac death in 3, and noncardiac death in 2. Of the remaining
171 patients, 109 (63.7%) were identiﬁed as volume respon-
ders to CRT. Clinical outcomes were assessed as the composite
endpoint of cardiac death or unplanned hospitalization for heart
failure. Cardiac death was deﬁned as death from worsening of
heart failure, coronary artery disease, cardiac arrhythmia, or
sudden cardiac death. Unplanned hospitalization for heart
failure was deﬁned as a hospital admission by the occurrence
of increasing symptoms and the need for treatment with
intravenous or oral medications for heart failure.
Echocardiographic Studies
E/E0, left atrial volume index (LAVI), mitral regurgitation (MR)
index, interventricular mechanical delay, and septal-to-poster-
ior wall motion delay on the M-mode image were measured by
previously reported methods.8,15 STE studies were performed
at a LV short-axis plane at the papillary muscle level and at
the apical 4-chamber, 2-chamber, and long-axis planes.
Images were recorded and analyzed using workstations with
vendor software packages (EchoPac PC v.7.0.1; GE Health-
care, Little Chalfont, UK; 2D Wall Motion Tracking; Toshiba
Medical Systems Corporation, Tokyo, Japan).
In the START study, 6 parameters in each radial strain,
circumferential strain (CS), and longitudinal strain compo-
nent were measured. We measured and compared 2 strain
peak points: Time from QRS onset to maximum strain (Tmax)
and that to ﬁrst peak in the multiple strain peaks (Tﬁrst)
were measured in each segment. Three dyssynchrony
parameters in each of Tmax and Tﬁrst were calculated as
follows: ﬁrst, the standard deviation of Tmax (TmaxSD) and
Tﬁrst (TﬁrstSD); second, the time difference (TD) between
the smallest Tmax and largest Tmax (TmaxTD) and between
the smallest Tﬁrst and largest Tﬁrst (TﬁrstTD); and third, TD
between the septum and lateral wall (TmaxTDSL,
TﬁrstTDSL). Among the 18 dyssynchrony parameters
derived from STE, TﬁrstSD of CS (TSD) showed the best
predictive value for volume responders in a single-parameter
approach (Figure 1). Therefore, standard deviation of time
from QRS onset to ﬁrst peak on the circumferential strain
curves (TSD) was used as the surrogate parameter of
dyssynchrony in this study.
Statistical Analysis
Multivariable diagnostic model
The probability of being a CRT responder was calculated by a
multivariable logistic regression analysis with forward selec-
tion method based on a likelihood ratio. The initially included
covariates are listed in Table 1. Each numerical parameter
was categorized as a binary based on the best cut-off value
point, which was deﬁned as the point with the highest sum of
sensitivity and speciﬁcity by ROC curve analysis. A calculated
value (Y) was obtained by a multiple regression equation,
which consisted of selected factors from a multivariable
logistic regression analysis with forward selection method.
Because Y is equal to log (probability/1probability), the
probability of being a CRT responder was calculated by the
following formula:
Probability ¼ 1=ð1þ expð1 YÞÞ
To assess the incremental value of TSD, the probability by a
logistic regression analysis model, in which TSD was not
included (model 1), was compared with that by the other
model including TSD (model 2). A probability of 0.5 was used
as the threshold for responders; if the probability value was
more than 0.5, the patient was classiﬁed as a responder.
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Assessment of incremental value of the strain
parameter
First, a c-statistic, which was calculated as an AUC, was
compared between models 1 and 2. Second, the incre-
mental effects of adding TSD to predict volume responders
were assessed by NRI and IDI.10 NRI and IDI are superior
methods for assessing the incremental value of perform-
ing a presumably better technique in place of a less-
accurate technique. Compared to c-statistic values, NRI
and IDI can reveal the percentage of a population that is
accurately reclassiﬁed, providing clinically meaningful
results rather than only statistically signiﬁcant differences
between c-statistic values. The reclassiﬁcation methods
are especially useful to address questions related to cost-
effectiveness.
NRI was calculated by the following formula:
NRI ¼ ½PðupjD ¼ 1Þ  PðdownjD ¼ 1Þ
 ½PðupjD ¼ 0Þ  PðdownjD ¼ 0Þ
where P is the proportion of patients, upward movement (up)
is deﬁned as a change into a higher probability of CRT
responder category based on model 1, and downward
movement (down) is deﬁned as a change in the opposite
direction. D denotes the response classiﬁcation: responder=1
or nonresponder=0.
IDI was calculated by the following formula:
IDI ¼ ½ðPextendedjD ¼ 1Þ  ðPbasicjD ¼ 1Þ
 ½ðPextendedjD ¼ 0Þ  ðPbasicjD ¼ 0Þ
In this equation, Pextended|D=1 and Pextended|D=0 are the
means of the predicted CRT responder probability by model 2
for, respectively, the CRT responder and the CRT nonrespon-
der, whereas Pbasic|D=1 and Pbasic|D=0 are the means of the
predicted CRT responder probability by model 1 for, respec-
tively, the CRT responder and the CRT nonresponder.
Third, the net beneﬁt of DCA was evaluated to assess the
clinical usefulness of TSD.
9,12 DCA is an approach that even
more explicitly quantiﬁes the clinical usefulness of a new test
when added to existing ones. In reclassiﬁcations including NRI
and IDI, a single predeﬁned probability threshold is chosen; a
probability of 0.5 was used as the threshold for responders in
our series to address the c-statistic value, NRI, and IRI. In
contrast, DCA allows each physician or patient to determine
his or her own desired threshold for further actions and judge
the corresponding net beneﬁts without explicitly assigning
weights or utilities to the false classiﬁcations. The expected
beneﬁt is represented by the true-positive rate, which is the
ratio of the number of CRT responders among patients who
will be predicted to be responders at a threshold probability to
all subjects. Contrastingly, the false-positive rate is the ratio
Figure 1. Time-circumferential strain (CS) curves. The ﬁgure shows time-CS curves on the midventricular
short-axis view obtained from a patient with idiopathic dilated cardiomyopathy. Each color curve is
corresponding to the same color segment of short-axis view as shown in the left upper panel;
yellow=anteroseptal wall, red=septal wall, blue=inferior wall, purple=posterior wall, green=lateral wall, and
light blue=anterior wall. The color point on the curve is the surrogate peak point in each segment. Time
from QRS onset (white perpendicular line) to the color point (Tﬁrst) is measured in each segment, and the SD
of Tﬁrst in 6 segments is calculated as TSD. AVC indicates aortic valve closure; ECG, electrocardiogram.
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of the number of CRT nonresponders among patients who will
be predicted to be responders at a threshold probability to all
subjects, and the expected harm is represented by a false-
positive rate multiplied by a weighting factor based on the
patient’s threshold probability. Then, net beneﬁt is calculated
by the following formula:
Table 1. Baseline Patient Characteristics by Tertile of the START Score
START Score Total (N=171)
T1 (N=56) T2 (N=55) T3 (N=60)
P Value0 to 9 10 to 13 14 to 17
Age, y 6612 6613 6713 6612 0.90
Male 113 (66) 39 (70) 33 (60) 41 (68) 0.51
Ischemic etiology 33 (19) 15 (27) 10 (18) 8 (13) 0.18
NYHA class II/III/IV 62/101/8 (36/59/5) 19/36/1 (34/64/2) 25/26/4 (46/47/7) 18/39/3 (30/65/5) 0.22
Heart rate, bpm 6814 6915 6913 6512 0.35
SBP, mm Hg 10718 10522 10714 10917 0.45
QRS duration, ms 15930 14428 15931* 17125† <0.001
LBBB or RV pacing 86 (50) 18 (32) 43 (78) 57 (95) <0.001
Sustained VT/VF 40 (23) 13 (23) 11 (20) 16 (27) 0.23
Hypertension 63 (37) 21 (38) 16 (29) 26 (43) 0.28
Diabetes mellitus 54 (32) 20 (36) 17 (31) 17 (28) 0.68
Laboratory data
Hb, g/dL 12.72.2 12.52.3 12.62.2 12.92.0 0.74
Albumin, g/dL 3.90.5 3.90.4 3.80.5 4.00.4 0.12
BUN, mg/dL 27.923.3 36.533.4 26.114.4 21.612.6†,* 0.002
Cre, mg/dL 1.51.7 2.02.5 1.41.3 1.10.9‡ 0.02
Sodium, mEq/L 1383.7 1373.8 1383.2 1393.7‡ 0.04
BNP, pg/m 700950 965989 626805‡ 520620† 0.03
Medication
ACE-I/ARB 130 (76) 41 (73) 39 (71) 50 (83) 0.25
Beta-blocker 138 (81) 37 (66) 44 (80) 57 (95) <0.001
Loop diuretics 142 (83) 51 (91) 43 (78) 48 (80) 0.14
Spironolactone 105 (61) 36 (64) 33 (60) 36 (60) 0.86
Echocardiography
LVEDV, mL 18990 19491 18668 185107 0.84
LVESV, mL 14181 14479 14058 13999 0.94
LVEF, % 276.9 276.7 256.5 277.3 0.18
LVDd, mm 649.5 679.3 647.4 6111† 0.01
LVDs, mm 5510 589.9 568.5 5210† 0.008
LVFS, % 145.7 145.9 135.6 155.4 0.09
E/E0 169.3 167.1 1610 1611 0.99
MR index, % 2419 3121 2218‡ 1714† <0.001
TSD, ms 13552 9241 13947† 17132†,* <0.001
Values aremeansSDor numbers (%). ACE-I indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen;
Cre, creatinine; E, early diastolic peak velocity of Doppler transmitral ﬂow; E0 , early diastolic mitral annular velocity; Hb, hemoglobin; LBBB, left bundle branch block; LVDd, left ventricular
dimension at end diastole; LVDs, left ventricular dimension at end systole; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-
systolic volume; LVFS, left ventricular fractional shortening;MR,mitral regurgitation; NYHA, New York Heart Association; RV, right ventricular; T, tertile; TSD, standard deviation of time fromQRS
onset to ﬁrst peak on the circumferential strain curves; START, Speckle Tracking imaging for the Assessment of cardiac Resynchronization Therapy; VT/VF, ventricular tachycardia/ﬁbrillation.
*P<0.01 versus T2.
†P<0.001.
‡P<0.05 versus T1.
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Net benefit¼ true positive rateweighting factor
 false positive rate¼ true positive cases=
Nweighting factor false positive cases=N
where N=number of all subjects and weighting fac-
tor=threshold probability/1threshold probability.
A net beneﬁt was calculated from 0.0 to a zero cross-point
at an interval of 0.05 of threshold probability. Based on the
net beneﬁt at each threshold probability, DCA generates a
graph of net beneﬁt as a function of a threshold probability of
a CRT responder at which an individual considers the potential
beneﬁt and harm of CRT to be equivalent.
Clinical scoring system
Each of the binary parameters was assigned a score based
on the regression coefﬁcient in the predictive formula of
model 2. The parameter with the lowest regression
coefﬁcient among the selected parameters in the model
was assigned the lowest integer number, and the others
were assigned scores of integer numbers based on the
values of their regression coefﬁcients relative to that of the
lowest value.16 The sum of each parameter point was
calculated as a START score. In addition, based on the
previous report from the Multicenter Automatic Deﬁbrillator
Implantation Trial with Cardiac Resynchronization Therapy
(MADIT-CRT),16 the MADIT score was assessed A point for
pasts hospitalization for chronic heart failure was assigned
a numeric value of 1; female sex, nonischemic etiology,
QRS duration ≥150 ms, left bundle branch block (LBBB),
and LV end-systolic volume index ≥125 mL/m2 were each
assigned a value of 2; and LAVI <40 mL/m2 was assigned
a value of 3. An individual MADIT score was calculated as a
sum of each factor point. C-statistics for CRT responders
were compared between the START score and MADIT score.
NRI and IDI also were assessed between both scoring
systems. DCA was also used to assess the clinical
usefulness of the START score.
Results are expressed as number (%) or as meanSD.
Comparisons between 2 groups were performed using the
Student t test for continuous variables and the v2 test for
categorical variables. One-way ANOVA with the post-hoc
Tukey-Kramer test was used to compare variables between 3
or more groups.
Kaplan–Meier analysis was done to determine the inﬂu-
ence of START scores on the endpoints. The risk of clinical
endpoints was determined with Cox proportional hazard
models. The univariate factors with a value of P<0.05 were
entered into the multivariable model adjusted for age and sex
to assess the effect of the parameters on the endpoints. A
P<0.05 was considered to indicate statistical signiﬁcance.
Analyses were performed with SPSS software (version 17.0;
SPSS Inc., Chicago, IL). In addition, comparisons of c-
statistics were performed with Analyse-it (Analyse-it Software,
Ltd., UK).
Results
Selected parameters and the statistical results are summa-
rized in Table 2. In model 1, other than TSD, the same 5
factors as in model 2 were selected by a multivariable logistic
regression analysis with forward selection method based on a
likelihood ratio using the covariates listed in Table 1, except
for TSD. The c-statistics of models 1 and 2 were 0.86 (95% CI,
0.80–0.93; P<0.001) and 0.77 (95% CI, 0.7–0.84; P<0.001),
respectively. The c-statistic of model 1 was signiﬁcantly
higher than that of model 2 (P<0.001). NRI and IDI were
calculated between models 1 and 2. The reclassiﬁcation table
for our CRT responder example is shown in Table 3, with the
probability threshold at 0.5. Of the CRT responders, 17.4% (18
of 109+1 of 109) were reclassiﬁed between models 1 and 2.
For CRT nonresponders, this percentage was 22.6% (6 of
Table 2. Multivariate Logistic Regression Analysis for CRT Responders
Model 1 Model 2
R OR (95% CI) P Value R OR (95% CI) P Value
LBBB or RV pacing 1.57 4.81 (2.20–10.5) <0.001 1.04 2.82 (1.17–6.84) 0.02
Use of beta-blocker 1.69 5.40 (2.10–13.9) <0.001 1.65 5.20 (1.91–14.1) 0.001
BUN ≤30 mg/dL 1.42 4.15 (1.78–9.68) 0.001 1.37 3.95 (1.60–9.72) 0.003
LVDs ≤50 mm 1.42 4.13 (1.56–10.9) 0.004 1.25 3.48 (1.26–9.66) 0.02
MR index ≤40% 1.32 3.74 (1.48–9.46) 0.005 1.08 2.95 (1.05–7.30) 0.01
TSD ≥116 ms — — — 1.99 7.28 (3.14–16.9) <0.001
Intercept 4.14 0.02 <0.001 4.63 0.01 <0.001
BUN indicates blood urea nitrogen; CRT, cardiac resynchronization therapy; LBBB, left bundle branch block; LVDs, left ventricular dimension at end systole; MR, mitral regurgitation; OR,
odds ratio; R, regression coefﬁcient; RV, right ventricular; TSD, standard deviation of time from QRS onset to ﬁrst peak on the circumferential strain curves.
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62+8 of 62). The NRI was (18 of 1091 of 109)(6 of 628
of 62)=0.16+0.03=0.19 (95% CI, 0.16–0.22; P<0.001). Fur-
thermore, the IDI for our CRT example was (0.830.80)
(0.220.36)=0.17 (95% CI, 0.11–0.22; P<0.001).
The decision curves for models 1 and 2 are shown in
Figure 1. Two additional decision guidance approaches (CRT
for no one and CRT for everyone based on the current
guideline, regardless of risk) were also incorporated for
comparison. Figure 2 shows that the net beneﬁt by the model
2 approach was higher than that by the model 1 approach
with threshold probabilities ≥0.2, which means the optimal
approach to guide decision making was model 2.
START Score
Based on model 2 (Table 2), each point in the START score
was assigned a value as follows: a point for LBBB or right
ventricular (RV) pacing and MR index ≤40% was assigned a
numeric value of 2; use of beta-blocker, blood urea nitrogen
(BUN) ≤30 mg/dL, and LV dimension at end systole (LVDs)
≤50 mm were each assigned a numeric value of 3; and CS-SD
≥116 ms was assigned a numeric value of 4. The c-statistic of
the START score was 0.86 (95% CI, 0.79–0.92; P<0.001). The
relation between the probability of CRT responders and the
START score is shown in Figure 3. A probability >0.5
corresponded to a START score ≥10, and a probability >0.9
corresponded to a score of ≥14. Tertiles of the START can be
compared in Table 1.
The c-statistic of the MADIT score was 0.66 (95% CI, 0.58–
0.75; P<0.001), which was signiﬁcantly lower than that of the
START score (P<0.001). The NRI of the START score
compared with the MADIT score was (9 of 1096 of 109)
(2 of 6228 of 62)=0.03+0.42=0.45 (95% CI, 0.41–0.49;
P<0.001), and the IDI was (0.840.80)(0.650.76)=0.15
(95% CI, 0.10–0.20; P<0.001; Table 4). Decision curves from
the START score and the MADIT score are shown in Figure 4.
Net beneﬁt was higher with threshold probabilities ≥0.2 by
the START score approach than by the MADIT score approach.
The cut-off value, whichwas determined as the point with the
highest sum of sensitivity and speciﬁcity by ROC analysis, was
identiﬁed as a START score of 12 to predict clinical outcomes.
Kaplan–Meier estimates of the time to endpoint are shown in
Figure 5. There were signiﬁcant differences between groups
(log rank, P<0.01). In the multivariable Cox proportional hazard
model analysis adjusted for age, sex, ischemic cardiomyopathy,
use of loop diuretics, and left ventricular end-diastolic volume
≥250 mL, a START clinical score ≤12 was identiﬁed as a
Table 3. Reclassiﬁcation Table From Model 1 and Model 2 at
an Arbitrary Cut-off Value of 0.5
CRT Responders (N=109)
Model 2
>0.5 ≤0.5 Total
Model 1 >0.5 82 1 83
≤0.5 18 8 26
Total 100 9 109
CRT Nonresponders (N=62)
Model 2
>0.5 ≤0.5 Total
Model 1 >0.5 12 8 20
≤0.5 6 36 42
Total 18 44 62
A patient with a model probability of >0.5 is considered with high probability to be a CRT
responder. Blue and red areas indicate reclassiﬁcations by model 2. CRT indicates
cardiac resynchronization therapy.
Figure 2. Decision curve analysis for multivariable logistic
regression models to predict responders of cardiac resynchro-
nization therapy. The thick black line is the net beneﬁt of referring
none of the patients for reference testing. The purple curve is the
net beneﬁt of referring all patients for reference testing, the gray
curve is the basic prediction model (model 1), and the red curve is
the extended prediction model (model 2), depending on the
choice of probability threshold.
Figure 3. The relation between the probability of being a
responder to cardiac resynchronization therapy (CRT) and the
Speckle Tracking imaging for the Assessment of cardiac Resyn-
chronization Therapy (START) score.
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signiﬁcant predictor of the endpoints (P=0.001; hazard ratio
[HR], 3.9; 95% CI, 1.2–5.0) as was a serum creatinine level
≥1.0 mg/dL (P=0.02; HR, 2.4; 95% CI, 1.8–8.7).
Discussion
The present study using data from the START study revealed
the incremental value of a STE parameter to predict CRT
responders using various statistical analyses. In the compar-
ison of the multivariable logistic regression models, model 2,
consisting of QRS morphology, degree of LV dilatation
measured by LVDs, use of beta-blocker, BUN level, and
mechanical dyssynchrony assessed by TSD with the other
model; model 1, in which TSD was excluded; c-statistics to
compare overall diagnostic accuracy between models 1 and 2;
NRI and IDI to assess overall improvement of reclassiﬁcations
from models 1 to 2; and DCA to quantify the clinical
usefulness of TSD, when added to model 1, all revealed that
model 2 including TSD improved the accuracy of the prediction
of CRT responders. On the basis of model 2, we created a
clinical scoring system, the START score, which was more
reliable in predicting CRT responders than the MADIT score in
our series. To our knowledge, this is the ﬁrst study using DCA
to examine the clinical usefulness of the dyssynchrony
parameter to predict CRT responders.
Combined Assessments to Predict CRT
Responders
In the START study,8 we showed that the strain parameter,
TSD, was the best predictor of CRT responders in a single-
parameter approach. However, our previous study did not
reveal the incremental value of TSD when added to the other
clinical determinants of CRT responses. Based on the current
guideline, 30% to 40% of patients do not show signiﬁcant LV
reverse remodeling post-CRT, which was also observed in
previous studies.1–3 Therefore, various factors, including types
of intraventricular conduction delays, sex, etiology of LV
dysfunction, severity of mitral regurgitation, LV diastolic
dysfunction, and presence of intra-, inter-, and atrioventricular
mechanical dyssynchrony, were reported as the novel factors
Table 4. Reclassiﬁcation Table From the MADIT Score and
the START Clinical Score at an Arbitrary Cut-off Value of 0.5
CRT Responders (N=109)
START Score
>0.5 ≤0.5 Total
MADIT Score >0.5 91 6 97
≤0.5 9 3 12
Total 100 9 109
CRT Nonresponders (N=61)
START Score
>0.5 ≤0.5 Total
MADIT Score >0.5 16 28 44
≤0.5 2 16 18
Total 18 44 62
A patient with a model probability of >0.5 is considered with high probability to be a CRT
responder. Blue and red areas indicate reclassiﬁcations by model 2. CRT indicates
cardiac resynchronization therapy; MADIT, Multicenter Automatic Deﬁbrillator
Implantation Trial; START, START, Speckle Tracking imaging for the Assessment of
cardiac Resynchronization Therapy.
Figure 4. Decision curve analysis for the Speckle Tracking
imaging for the Assessment of cardiac Resynchronization Therapy
(START) score and the Multicenter Automatic Deﬁbrillator
Implantation Trial (MADIT) score to predict responders of cardiac
resynchronization therapy. The red curve is the net beneﬁt of
treating patients according to the START score, and the gray
curve is the net beneﬁt of treating patients according to the
MADIT score. As in Figure 1, the thin black line is the net beneﬁt
of referring none of the patients for reference testing, and the
purple curve is that of referring all patients for reference testing.
Figure 5. Kaplan–Meier curves for the probability of freedom
from cardiac death and unplanned hospitalizations for heart
failure. START indicates Speckle Tracking imaging for the
Assessment of cardiac Resynchronization Therapy.
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that improve the accuracy of predicting CRT responders.16,17
However, a single parameter is limited in its ability to predict
responses accurately because multivariable factors affect the
responses to CRT.9 Therefore, combined assessment of
factors that are associated with favorable reverse remodeling
post-CRT can be used to predict clinical response to the
device as was shown in the MADIT-CRT study.16
START Score
Because the main subjects in the MADIT-CRT study were
patients classiﬁed as NYHA class I or II, it is unknown whether
the MADIT scoring system can be used to make extrapolations
in patients classiﬁed as NYHA class III or IV.16 Park et al18
reported that the echocardiographic score more accurately
predicted LV reverse remodeling with CRT, and, compared to
the MADIT score, it predicts clinical outcomes in 90% of
patients classiﬁed as NYHA class III or IV. However, the
echocardiographic score of these patients does not even
include LBBB, which is the established clinical parameter. We
hypothesized that other factors, including medications, other
organ failure, and structural heart diseases, also could affect
LV reverse remodeling post-CRT. Therefore, we performed a
multivariable logistic regression analysis to select signiﬁcant
variables among various clinical covariates to construct our
original scoring system to predict CRT responders. Compared
to the other scoring systems, our START score includes unique
parameters, which are BUN level and the use of beta-blocker.
An elevated BUN level in heart failure is associated with
enhanced proximal and distal tubular reabsorption of urea,
being linked to the reabsorption of sodium and water under
the effects of the renin-angiotensin-aldosterone and beta-
adrenergic systems.19–21 Because neurohormonal factors
aggravate myocardial dysfunction,21 a lower BUN level means
a more-favorable condition for the myocardium and neurohor-
monal circumstances to respond more readily to CRT. As well,
the use of beta-blockers, which are the ﬁrst-line medications
for heart failure, provides a better condition for CRT, but also
synergistically improves myocardial function.22,23 Considering
the complex pathophysiology of heart failure, it is important to
include neurohormonal factors in the START score.
However, as aforementioned, our START score was created
based on the multivariable logistic regression analysis.
Because each parameter was obtained from post-hoc deﬁni-
tions, the score should be considered as preliminary ﬁndings.
Therefore, the reliability of the START score needs to be
validated in the other cohort prospectively.
Reclassiﬁcation and DCA
Reclassiﬁcation measures (NRI and IDI) have been of major
importance in assessing the added value estimations of a
biomarker or a test.24 However, NRI and IDI provide no
information about whether the diagnostic probabilities calcu-
lated with a diagnostic model are in agreement with the
observed CRT responder rate.9,11 In the present study, the
probability to calculate NRI and IDI, and c-statistics, was ﬁxed
at 0.5. In contrast, DCA, which has already been used in
clinical studies, is a novel method with the following
concepts.9,12–14 The probability threshold—a level of diag-
nostic certainty above which the patient would choose to be
treated—is the key in DCA. Unlike reclassiﬁcation measures,
the incremental value of the diagnostic method can be
clariﬁed at an arbitrary probability. Second, DCA can take into
account risk threshold, weighting beneﬁts, and harms and is
useful in evaluating the clinical utility of a prediction model. In
this study, the expected harm is represented by the number of
nonresponders who would be treated in error (false positives)
multiplied by a weighting factor based on the patient’s
threshold probability. In a case that a physician strongly
expects to be a CRT responder, the probability threshold will
be higher. As shown in Figure 3, the DCA curve of model 2 is
highest at probability thresholds >0.2, which means a
multivariable approach including the mechanical dyssyn-
chrony measure by STE would be the best decision approach
for all patients in our series. The differences between the
curves are wider as the probability thresholds increase,
indicating the more-incremental value of the mechanical
dyssynchrony measure by STE if the intent is to avoid
nonresponders. As well, the START score may be more useful
compared to the MADIT score. The present results were
consistent with a study that evaluated the usefulness of a
multiparametric echocardiographic score method for CRT
responders.18 In addition, we found that the START score was
an independent predictor of clinical outcomes, which supports
the ﬁnding in previous studies that patients with reverse
remodeling have more-favorable long-term survival than those
without reverse remodeling post-RT.6–8,16
Limitations
The START study is a multicenter study, but the number of
patients is small compared to a large-scale study like the
MADIT-CRT study.16 Thus, the statistical power might not be
adequate to identify the determinants of CRT responders. In
addition, this study consisted of Japanese participants only.
The number of patients with ischemic heart disease in Japan is
less than that in Western developed countries. In this study,
only 19% of patients had ischemic heart disease, which might
make the START score speciﬁc to our series. Thus, in the
future, large-scale, prospective studies will be needed to
conﬁrm the clinical usefulness of the START score.
Myocardial scar burden or presence of scar at a pacemaker
lead implantation site on the LV free wall is well known to be a
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determinant of CRT responses. However, we did not assess
myocardial scar or myocardial viability using cardiac magnetic
resonance imaging, nuclear imaging, or stress echocardiogra-
phy. Therefore, the START clinical score might be modiﬁed if
myocardial scar or myocardial viability assessments were also
included in multivariable logistic regression analyses.
Conclusions
Based on various statistical methods, including DCA, mechan-
ical dyssynchrony assessment by STE was revealed to have an
incremental value to predict CRT responders. STE may
contribute to decision making for CRT indications, particularly
if nonresponders are to be avoided in the clinical setting.
Given that this study was performed based on the post-hoc
analyses, the ﬁndings including our clinical score need to be
validated in the other cohort prospectively.
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